Accelerating Pneumococcal Conjugate Vaccine introductions in Indonesia:key learnings from 2017 to 2022  

作　　者：Anithasree Athiyaman Putri Herliana Atiek Anartati Niken Widyastuti Prima Yosephine Gertrudis Tandy Sherli Karolina 

机构地区：[1]Global Vaccines Delivery,Clinton Health Access Initiative,Boston,USA [2]Country Ofce,Clinton Health Access Initiative,Jakarta,Indonesia [3]Directorate of Immunization,Ministry of Health,Republic of Indonesia,Jakarta,Indonesia

出　　处：《Infectious Diseases of Poverty》2023年第6期91-95,共5页贫困所致传染病（英文）

基　　金：This work was made possible through funding support from Bill and Melinda Gates Foundation.

摘　　要：Despite high pneumococcal disease and economic burden in Indonesia and interest to introduce pneumococcal conjugate vaccine (PCV), there were challenges in establishing a comprehensive strategy to accelerate and enable the introduction in country in the early 2010s. Starting in 2017, Clinton Health Access Initiative and partners supported the government of Indonesia with evidence-based decision-making and implementation support for introducing PCV into the routine immunization program. Indonesia has since accelerated PCV roll out, with nationwide reach achieved in 2022. On the path to PCV introduction, several challenges were observed that impacted decision making on whether and on how to optimally roll out PCV, resulting in significant introduction delays;including (1) a complex country context with a devolved government structure, fragmented domestic funding streams, and an imminent transition out of major immunization donor (Gavi) support;(2) strong preference to use domestically sourced products, with limited experience accessing global pooled procurement mechanism including for vaccines;and (3) concerns around programmatic feasibility and sustainability. This case study documents key insights into the challenges experienced and how those were systematically addressed to accelerate new vaccine introduction in Indonesia, with support from local and global stakeholders over time. The learnings would be beneficial for other countries yet to introduce critical new vaccines, in particular those with similar archetype as Indonesia e.g., middle-income countries with domestic manufacturing capacity and/or countries recently transitioning out of Gavi support.

关 键 词：New vaccine introduction IMMUNIZATION Indonesia Pneumococcal conjugate vaccines SUSTAINABILITY COVERAGE Gavi 

分 类 号：R511[医药卫生—内科学] R186[医药卫生—临床医学]